Brain Tumor Drugs Market Outlook 2026–2030: Key Business Drivers and Trends

Uncover key drivers, emerging technologies, and competitive movements shaping the brain tumor drugs market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Brain Tumor Drugs Market in 2026, and what figure is it projected to hit by 2030?

The brain tumor drugs market has seen robust expansion in recent years. It is anticipated to increase from $4.03 billion in 2025 to $4.26 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.7%. Historically, this market’s development has been propelled by factors including the increasing incidence of brain tumors, advancements in chemotherapy drugs, greater awareness regarding symptom management, the emergence of hormone therapies, and the introduction of novel anticonvulsants.

The market for brain tumor drugs is projected to experience substantial expansion in the coming years. This market is anticipated to reach $5.5 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.6%. Factors driving this growth during the forecast period include the advancement of precision medicine, the incorporation of AI into drug discovery processes, increased research and development efforts in oncology, higher healthcare spending, and the growing use of targeted therapies. Key trends anticipated during this period encompass personalized chemotherapy approaches, an increase in the application of hormone therapy, the development of advanced pain management medications, a greater reliance on anticonvulsants for symptom management, and the broadening of drug pipelines for brain tumors.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2588&type=smp

Which Drivers Are Affecting Market Participation In The Brain Tumor Drugs Market?

The growing count of patients receiving chemotherapy is projected to advance the brain tumor drugs market in the future. Chemotherapy, a medical treatment, employs potent medications to specifically target and eliminate rapidly dividing cells, including cancer cells. It functions as a principal treatment approach for brain tumors, where the innovation and accessibility of effective chemotherapy agents significantly influence the overall triumph of therapies. The effectiveness of chemotherapy is vital in prolonging patient survival and enhancing their quality of life, thereby influencing the market’s progression. For example, in July 2023, the Centers for Disease Control and Prevention, a US-based government agency, stated that in the United States, more than 1 million cancer patients undergo chemotherapy or radiation annually. Consequently, the rising number of individuals receiving chemotherapy is propelling the expansion of the brain tumor drug market.

What Segment Categories Are Covered In The Brain Tumor Drugs Market?

The brain tumor drugs market covered in this report is segmented –

1) By Drugs: Temozolomide, Bevacizumab, Other Drugs

2) By End User: Hospital Pharmacies, Retail Pharmacies Or Drug Stores, Other End-Users

3) By Mechanism of Action: Chemotherapy Agents, Targeted Therapy, Hormone Therapy

Subsegments:

1) By Temozolomide: Oral Formulation, Injectable Formulation

2) By Bevacizumab: Monoclonal Antibody Therapy, Combination Therapy With Chemotherapy

3) By Other Drugs: Carmustine, Lomustine, Etoposide, Irinotecan, Novantrone (Mitoxantrone)

What Industry Trends Are Transforming The Brain Tumor Drugs Market?

Leading companies in the brain tumor drugs market are concentrating on technological advancements, such as targeted RAF kinase inhibitors, to meet the growing demand for precision oncology treatments. These treatments aim to target specific genetic mutations within brain tumors, thereby reducing systemic toxicity and improving patient outcomes. A RAF kinase inhibitor is a medication designed to specifically block the activity of RAF proteins, which are part of the MAPK signaling pathway, consequently inhibiting tumor cell proliferation; this method stands in contrast to traditional chemotherapies that non-specifically kill rapidly dividing cells and frequently cause broader systemic side effects. For instance, in November 2025, Day One Biopharmaceuticals, a US-based biotechnology company, launched OJEMDA (tovorafenib), an innovative therapy intended for pediatric patients with relapsed or refractory low-grade gliomas harboring BRAF fusions or V600 mutations. Tovorafenib is an orally administered, once-weekly, brain-penetrant inhibitor that precisely targets mutant RAF proteins, providing strong central nervous system exposure and a mechanism tailored to the tumor’s molecular driver. Its unique features include high selectivity, reduced systemic toxicity when compared with traditional chemotherapy, and suitability for pediatric patients. This product represents a significant step forward in genetically guided therapy for childhood brain tumors.

Which Major Industry Participants Are Leading The Brain Tumor Drugs Market Growth?

Major companies operating in the brain tumor drugs market are F. Hoffmann-La Roche Ltd, Novartis AG, Amgen Inc., Pfizer Inc., Merck & Co. Inc., CordenPharma, Eisai Co. Ltd., Emcure Pharmaceuticals Limited, Y-mAbs Therapeutics, Roche India, Novartis Oncology, Arlak Biotech, Healthkind Labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd, Apikos Pharma, Kolaz Biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Astellas Pharma Inc, Otsuka Pharmaceutical Co. Ltd, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc. (UK), AstraZeneca plc, GlaxoSmithKline plc, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celgene Corporation, Johnson & Johnson, Eli Lilly and Company, Sandoz AG, Eurofarma Laboratórios S.A., TUTEUR Argentina, The Takeda Pharmaceutical Company Limited, Pierre Fabre Group, Celnova Pharma, Pfizer S.R.L., Teva Pharmaceutical Industries Ltd., BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Julphar, Sanofi, Novo Nordisk A/S, Bayer, Kitov Pharma Limited, CureTech Ltd., Neopharma, Eurolab, Aspen, Adcock Ingram.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Brain Tumor Drugs Market?

North America was the largest region in the brain tumor drugs market in 2025. Middle East is expected to be the fastest-growing region in the global brain tumor drugs market share during the forecast period. The regions covered in the brain tumor drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Brain Tumor Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2588&type=smp

Browse Through More Reports Similar to the Global Brain Tumor Drugs Market 2026, By The Business Research Company

Brain Tumor Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report

Pontine Glioma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/pontine-glioma-drugs-global-market-report

Adult Malignant Glioma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/adult-malignant-glioma-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795